Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Headache
|
October 24, 2025
A phase 1, multicenter, open-label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine
Chay Ngee Lim, Gary Mo, Rajinder Bhardwaj, et al.
British Journal of Clinical Pharmacology
|
April 30, 2014
Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice
Vidya Perera, Robert R Bies, Gary Mo, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
August 24, 2012
Differential expression and pharmacology of native P2X receptors in rat and primate sensory neurons
Alexandre Serrano, Gary Mo, Rebecca Grant, et al.
Cancer Medicine
|
December 11, 2019
Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma
Victor M Villalobos, Gary Mo, Mark Agulnik, et al.
Clinical and Translational Science
|
April 11, 2025
AI-Driven Applications in Clinical Pharmacology and Translational Science: Insights From the ASCPT 2024 AI Preconference
Mohamed H Shahin, Prashant Desai, Nadia Terranova, et al.
Cancer Medicine
|
January 21, 2021
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors
Leo Mascarenhas, Chitose Ogawa, Theodore W Laetsch, et al.
Molecular Cancer Therapeutics
|
November 12, 2020
Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
Javier Martín-Broto, Antonio López Pousa, Andrew S Brohl, et al.
Pain
|
May 26, 2009
The beta3 subunit of the Na+,K+-ATPase mediates variable nociceptive sensitivity in the formalin test
Michael L LaCroix-Fralish, Gary Mo, Shad B Smith, et al.
JAMA
|
April 8, 2020
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial
William D Tap, Andrew J Wagner, Patrick Schöffski, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Headache
|
October 24, 2025
A phase 1, multicenter, open-label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine
Chay Ngee Lim, Gary Mo, Rajinder Bhardwaj, et al.
British Journal of Clinical Pharmacology
|
April 30, 2014
Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice
Vidya Perera, Robert R Bies, Gary Mo, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
August 24, 2012
Differential expression and pharmacology of native P2X receptors in rat and primate sensory neurons
Alexandre Serrano, Gary Mo, Rebecca Grant, et al.
Cancer Medicine
|
December 11, 2019
Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma
Victor M Villalobos, Gary Mo, Mark Agulnik, et al.
Clinical and Translational Science
|
April 11, 2025
AI-Driven Applications in Clinical Pharmacology and Translational Science: Insights From the ASCPT 2024 AI Preconference
Mohamed H Shahin, Prashant Desai, Nadia Terranova, et al.
Cancer Medicine
|
January 21, 2021
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors
Leo Mascarenhas, Chitose Ogawa, Theodore W Laetsch, et al.
Molecular Cancer Therapeutics
|
November 12, 2020
Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
Javier Martín-Broto, Antonio López Pousa, Andrew S Brohl, et al.
Pain
|
May 26, 2009
The beta3 subunit of the Na+,K+-ATPase mediates variable nociceptive sensitivity in the formalin test
Michael L LaCroix-Fralish, Gary Mo, Shad B Smith, et al.
JAMA
|
April 8, 2020
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial
William D Tap, Andrew J Wagner, Patrick Schöffski, et al.
Page
of 2